Maintenance fees coming due
Corcept Therapeutics Incorporated
13 maintenance fees come due in the 12 months from Nov 17, 2026, the next on Dec 18, 2026. Unpaid by Jun 21, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 10,323,034 | Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators In force Fee due Dec 18, 2026 Lapses if unpaid Jun 21, 2027 · High confidence | Corcept Therapeutics, Inc. | In force | Dec 18, 2026 | Jun 21, 2027 | High confidence | |
| US 11,684,612 | Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator In force Fee due Dec 27, 2026 Lapses if unpaid Jun 28, 2027 · High confidence | Corcept Therapeutics Incorporated | In force | Dec 27, 2026 | Jun 28, 2027 | High confidence | |
| US 11,760,731 | Polymorphs of Pyrimidine Cyclohexyl Glucocorticoid Receptor Modulators In force Fee due Mar 19, 2027 Lapses if unpaid Sep 20, 2027 · High confidence | Corcept Therapeutics Incorporated | In force | Mar 19, 2027 | Sep 20, 2027 | High confidence | |
| US 11,787,780 | Quaternary Indazole Glucocorticoid Receptor Antagonists In force Fee due Apr 17, 2027 Lapses if unpaid Oct 18, 2027 · High confidence | Corcept Therapeutics Incorporated | In force | Apr 17, 2027 | Oct 18, 2027 | High confidence | |
| US 10,449,178 | Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer In force Fee due Apr 22, 2027 Lapses if unpaid Oct 22, 2027 · High confidence | Corcept Therapeutics, Inc. | In force | Apr 22, 2027 | Oct 22, 2027 | High confidence | |
| US 11,827,608 | Method of Preparing Pyrimidine Cyclohexyl Glucocorticoid Receptor Modulators In force Fee due May 28, 2027 Lapses if unpaid Nov 29, 2027 · High confidence | Corcept Therapeutics Incorporated | In force | May 28, 2027 | Nov 29, 2027 | High confidence | |
| US 11,890,289 | Use of Glucocorticoid Receptor Antagonists in Combination with Glucocorticoids to Treat Adrenal Insufficiency In force Fee due Aug 6, 2027 Lapses if unpaid Feb 7, 2028 · High confidence | Corcept Therapeutics, Inc. | In force | Aug 6, 2027 | Feb 7, 2028 | High confidence | |
| US 11,903,945 | Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant In force Fee due Aug 20, 2027 Lapses if unpaid Feb 22, 2028 · High confidence | Corcept Therapeutics Incorporated | In force | Aug 20, 2027 | Feb 22, 2028 | High confidence | |
| US 11,925,626 | Pharmaceutical Formulations Containing Relacorilant, a Heteroaryl-Ketone Fused Azadecalin Compound In force Fee due Sep 12, 2027 Lapses if unpaid Mar 13, 2028 · High confidence | Corcept Therapeutics Incorporated | In force | Sep 12, 2027 | Mar 13, 2028 | High confidence | |
| US 11,944,617 | Concomitant Administration of Glucocorticoid Receptor Modulator Relacorilant and Paclitaxel, a Dual Substrate of CYP2C8 and CYP3A4 In force Fee due Oct 2, 2027 Lapses if unpaid Apr 3, 2028 · High confidence | Corcept Therapeutics Incorporated | In force | Oct 2, 2027 | Apr 3, 2028 | High confidence | |
| 3 more maintenance fees coming due in the 12 months from Nov 17, 2026 · Pro | |||||||
10 of 13 patents shown. Soonest fee due date first, then patent number.
Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.